Edesa Biotech (EDSA)
(Delayed Data from NSDQ)
$4.49 USD
+0.14 (3.22%)
Updated Sep 20, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
EDSA 4.49 +0.14(3.22%)
Will EDSA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EDSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for EDSA
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024
Edesa Biotech Showcases Steady Q3 2024 Financials
Edesa Biotech GAAP EPS of -$0.52 beats by $0.06
Edesa Biotech reports Q3 EPS (52c) vs (68c) last year
Promising Outlook for Edesa Biotech’s Paridiprubart: A Buy Rating Justified by BARDA-Backed ARDS Study and Broad Therapeutic Potential